Human Organoids Market size was expected to be worth USD 2,164.6 million in 2022 and is projected to grow at a 16.2% CAGR from 2023 to 2029. Organoids are stem cell-derived, small, self-organized three-dimensional tissue cultures. Such cultures can be designed to reproduce much of an organ's complexity or express specific features, such as producing only certain types of cells. Organoids develop from stem cells, which can proliferate endlessly and have various cell types as part of their progeny. Organoids range from less than a hair's breadth to five millimetres. Based on the product type, the global human organoid market is segmented into Liver, Kidney, Pancreas, Colorectal, Heart, and Others. The Liver segment is anticipated to grow at a significant CAGR over the forecast years, owing ascribed to greater acceptance of new technologies among academics and academia (combined with expanding industry-academia cooperation for genomic research), technological breakthroughs in 3D bioprinting, and an increase in the number of liver transplants and disorders. Factors such as market technology improvements are driving the expansion of the human organoids industry. Furthermore, increased transplant cases and investments from both the commercial and public sectors are influencing the growth of the human organoids industry.
Human Organoids Market Key Developments:
In May 2020, The Luxembourg Centre for Systems Biomedicine researchers built an organoid that can be used to study Parkinson's disease.
Fastest Growing Market
Animal models are commonly employed in human-specific scientific research. However, numerous situations show that animal models are not necessarily predictive of human drug response, such as in drug toxicology research. This is because the metabolism of medications and poisons differs significantly between humans and animals, making it practically hard to research drug metabolism in experimental models such as laboratory rodent species. Furthermore, various restrictions have been adopted in recent years that limit the use of animals in scientific operations worldwide. Similarly, some organizations, including Cruelty-Free International and the Fund for the Replacement of Animals in Medical Experiments, are against using animal-based models in research. It is vital to design alternative testing models to give an environment as close to the human body as possible. Various institutes are active in establishing alternate approaches for medication development and biological research considering this. Because organoids can be used instead of animal models in research, the current emphasis on minimizing animal use in research is projected to help the growth of the human organoids industry.
The growth in the clinical microbiology market is driven majorly by the rising incidence of transplants and technological advancements in human organoids, and increased funding and public-private investments.
The liver segment by type will show the most opportunity for growth.
BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden) are the leading players in the global Organoids market.
The lack of skilled professionals to conduct diagnostic tests and insufficient funding for research & academia are estimated to hamper the market growth.